GlycoMimetics Inc (GLYC) was Initiated by SunTrust to “Buy”. SunTrust advised their investors in a research report released on Jul 26, 2016.
GlycoMimetics Inc opened for trading at $7.96 and hit $8.15 on the upside on Wednesday, eventually ending the session at $8.1, with a gain of 2.53% or 0.2 points. The heightened volatility saw the trading volume jump to 35,776 shares. Company has a market cap of $157 M.
In a different news, on Jul 6, 2016, Helen M. Thackray (VP Clinical Development, CMO) sold 22,000 shares at $7.03 per share price. According to the SEC, on Mar 7, 2016, Mark Alan Goldberg (director) purchased 10,397 shares at $4.77 per share price.
GlycoMimetics Inc. (GlycoMimetics) is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs to address medical needs. The Company’s pipeline includes GMI-1070 (Rivipansel) GMI-1271 GMI-1359 (E-selectin and CXCR4 antagonist) GMI-1051 and Galectin inhibitors. The Company developing rivipansel to treat VOC (vaso-occlusive crisis) with the goal of reducing duration of VOC episodes length of hospital stay and use of opioid analgesics for pain management. The Company is developing GMI-1271 a specific E-selectin antagonist to be used in combination with chemotherapy to treat AML (acute myeloid leukemia) and other hematologic cancers. GMI-1359 simultaneously inhibits both E-selectin and CXCR4 for use in the treatment of cancers with bone marrow involvement such as myeloma. GMI-1051 is an antagonist of two pseudomonas virulence factors PA-IL and PA-IIL.